Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 20,694 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Peripheral Blood Clear all

Conditions: Grade 2 Meningioma, Grade 3 Meningioma, Recurrent Meningioma
Interventions: Biospecimen Collection, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Stereotactic Radiosurgery; Procedure · Biological · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 29
States / cities: Phoenix, Arizona • Duarte, California • La Jolla, California + 23 more

Conditions: Diabetes
Interventions: insulin regular IV infusion, IV insulin infusion; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy Participants
Interventions: Compression Boots; Device
Lead sponsor: University of Redlands; Other
Eligibility: 18 Years to 23 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Redlands, California

Conditions: Blood Loss
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Leukemia, Lymphoma
Interventions: rituximab, cyclophosphamide, pentostatin; Biological · Drug
Lead sponsor: Hoag Memorial Hospital Presbyterian; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Breast Cancer, Breast Neoplasms
Interventions: Genomic and/or molecular testing of blood or tissue; Other
Lead sponsor: Targeted Medical Education; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 4
States / cities: Los Gatos, California • Allentown, Pennsylvania • Nashville, Tennessee + 1 more

Conditions: Advanced Solid Cancers
Interventions: BMS-986301, Nivolumab, Ipilimumab; Drug · Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 4
States / cities: Chicago, Illinois • St Louis, Missouri • Pittsburgh, Pennsylvania + 1 more

Conditions: Memory Impairment
Interventions: Fruitflow-II, resVida; Drug
Lead sponsor: Neurolgy Institute for Brain Health and Fitness; Other
Eligibility: 50 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Lutherville, Maryland

Conditions: E-Aminocaproic Acid, Bilateral Varus Rotational Osteotomy
Interventions: E-Aminocaproic acid; Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 1 Year to 18 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Primary Myelofibrosis, Secondary Myelofibrosis
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, Methotrexate, Mycophenolate Mofetil, Ruxolitinib, Tacrolimus, Total-Body Irradiation, Umbilical Cord Blood Transplantation; Procedure · Drug · Other + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Idiopathic Angioedema
Interventions: Omalizumab, Placebos; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Cytomegalovirus Infections, Solid Organ Transplant
Interventions: CMV specific T-cells; Biological
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Melanoma
Interventions: Blood Sample Collection; Other
Lead sponsor: Exact Sciences Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 36
States / cities: Little Rock, Arkansas • Laguna Hills, California • Palm Springs, California + 32 more

Conditions: HER2/Neu Positive, Recurrent Breast Carcinoma, Stage IV Breast Cancer
Interventions: HER-2/neu Intracellular Domain Protein, Laboratory Biomarker Analysis, Pertuzumab, Placebo, Polysaccharide-K, Trastuzumab; Biological · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Bladder Cancer
Interventions: Gemcitabine,, Cisplatin, Cetuximab; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 14
States / cities: Duarte, California • Los Angeles, California • Stanford, California + 11 more

Conditions: Malignant Glioma
Interventions: Bevacizumab, Temozolomide, Vitamin C; Drug · Dietary Supplement
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Acute Kidney Injury in Pediatric Patients
Interventions: Prismaflex HF20 CRRT Filter, Prismaflex® System 7.10 and 7.20; Device
Lead sponsor: Vantive Health LLC; Industry
Eligibility: Not listed
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 6
States / cities: Stanford, California • Iowa City, Iowa • Grand Rapids, Michigan + 3 more

Conditions: Adverse Drug Reaction
Interventions: Pharmacogenetic Intervention Arm (pharmacogenetic testing); Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 4,465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Diabetes Mellitus Type 2
Interventions: Continuous Glucose Monitor, Glucometer; Device
Lead sponsor: Walter Reed Army Medical Center; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Advanced Acral Melanoma, Advanced Cutaneous Melanoma, Advanced Mucosal Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Acral Melanoma, Metastatic Cutaneous Melanoma, Metastatic Mucosal Melanoma, Unresectable Acral Melanoma, Unresectable Cutaneous Melanoma, Unresectable Mucosal Melanoma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Medical Device Usage and Evaluation, Nivolumab, Questionnaire Administration; Procedure · Biological · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: KidneyTransplant Recipients, Simultaneous Kidney/Pancreas Recipients, Kidney Transplant Donor
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 1,552 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 4
States / cities: Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota

Conditions: Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma
Interventions: Biopsy, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Glofitamab, Lenalidomide, Obinutuzumab, Positron Emission Tomography, Venetoclax; Procedure · Biological · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Duarte, California • New York, New York • Salt Lake City, Utah

Conditions: Metastatic Microsatellite-stable Colorectal Cancer
Interventions: Durvalumab, Oleclumab, FOLFOX, Bevacizumab; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 101 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 11
States / cities: Los Angeles, California • Sacramento, California • Ann Arbor, Michigan + 8 more

Conditions: B-cell Non-Hodgkin Lymphoma (B-NHL)
Interventions: UCART20x22, CLLS52; Biological
Lead sponsor: Cellectis S.A.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Chicago, Illinois • Boston, Massachusetts • New Brunswick, New Jersey + 1 more

Search by objective public record fields.

Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma

Comparison of the Leuven Protocol With the Glucommander for Postoperative Control of Blood Glucose With IV Insulin

The Effects of Recovery Compression Boots on Blood Lactate Levels, Functional Movement, and Joint Ange of Motion in Collegiate Athletes.

Comparative Accuracy of Three Versions of Non-Invasive Hemoglobin Monitoring

Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma

TME Neoadjuvant Breast Registry

An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers

Cerebrovascular and Cognitive Improvement by Resveratrol (resVida) and Fruitflow-II (CCIRF-II)

The Effect of Intravenous EACA on Blood Loss and Transfusion Requirements After Bilateral VRO

JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy

A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Solid Organ Transplant Recipients

Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Melanoma

Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy

Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer

A Phase I Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma

Prismaflex HF20 Set and Prismaflex® System 7.10/7.20 for Acute Continuous Renal Replacement Therapy (CRRT) in Children

A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program

Continuous Glucose Monitoring in Patients With Type 2 Diabetes

Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial

Genomics of Kidney Transplantation

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma